ATE116338T1 - Chemisch modifizierte proteine und deren herstellung. - Google Patents

Chemisch modifizierte proteine und deren herstellung.

Info

Publication number
ATE116338T1
ATE116338T1 AT87103259T AT87103259T ATE116338T1 AT E116338 T1 ATE116338 T1 AT E116338T1 AT 87103259 T AT87103259 T AT 87103259T AT 87103259 T AT87103259 T AT 87103259T AT E116338 T1 ATE116338 T1 AT E116338T1
Authority
AT
Austria
Prior art keywords
chemically modified
modified proteins
group
production
imidoester
Prior art date
Application number
AT87103259T
Other languages
English (en)
Inventor
Hayao Ueno
Masahiko Fujino
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE116338T1 publication Critical patent/ATE116338T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT87103259T 1986-03-10 1987-03-06 Chemisch modifizierte proteine und deren herstellung. ATE116338T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5306186 1986-03-10

Publications (1)

Publication Number Publication Date
ATE116338T1 true ATE116338T1 (de) 1995-01-15

Family

ID=12932327

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87103259T ATE116338T1 (de) 1986-03-10 1987-03-06 Chemisch modifizierte proteine und deren herstellung.

Country Status (8)

Country Link
US (1) US5109120A (de)
EP (1) EP0236987B1 (de)
JP (1) JP2514950B2 (de)
AT (1) ATE116338T1 (de)
CA (1) CA1336967C (de)
DE (1) DE3750906T2 (de)
ES (1) ES2065880T3 (de)
GR (1) GR3015558T3 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5714581A (en) * 1986-12-23 1998-02-03 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
JP3187044B2 (ja) * 1989-12-01 2001-07-11 ビーエーエスエフ アクチェンゲゼルシャフト ヒルジン突然変異蛋白質及びヒルジンポリアルキレングリコール複合体
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
EP0618927A4 (de) * 1991-12-10 1995-05-24 Tanox Biosystems Inc Cytokine mit einem ungepaarten cystein-rest und konjugaten davon.
WO1993013131A1 (fr) * 1991-12-24 1993-07-08 Sumitomo Seika Chemicals Co., Ltd. Procede pour la production d'un composite proteine/polymere synthetique et composite ainsi produit
US5414135A (en) * 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
TW263437B (de) * 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
FR2774687B1 (fr) * 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
KR100694345B1 (ko) 1998-05-15 2007-03-12 쉐링 코포레이션 리바비린 및 인터페론 알파를 포함하는, 만성 ｃ형 간염에 걸린 항-바이러스 치료에 대한 나이브 환자의 치료용 약제학적 조성물
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
CA2303992A1 (en) 1999-04-08 2000-10-08 Schering Corporation Melanoma therapy
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
IL149267A0 (en) 1999-11-12 2002-11-10 Maxygen Holdings Ltd Interferon gamma conjugates
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
DK1476181T3 (en) 2002-01-18 2016-05-23 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF
AU2003239774A1 (en) 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
JP2007526317A (ja) * 2004-03-01 2007-09-13 エンゾン ファーマスーティカルズ インコーポレイテッド インターフェロン−ベータ・ポリマー結合体
RU2427372C2 (ru) 2005-06-17 2011-08-27 Новартис Аг Применение санглиферина для лечения вируса гепатита с
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
GB2438834A (en) * 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
WO2009055343A2 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
PH12012500827A1 (en) 2009-10-30 2013-01-07 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
KR20140035305A (ko) 2010-10-05 2014-03-21 노파르티스 아게 C형 간염 바이러스 감염의 새로운 치료법
AU2011311880B2 (en) 2010-10-08 2014-07-24 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CN105381450A (zh) 2010-11-30 2016-03-09 诺华有限公司 丙型肝炎病毒感染的新疗法
CN105749246A (zh) 2011-03-31 2016-07-13 诺华股份有限公司 治疗丙肝病毒感染的阿拉泊韦
RS53911B1 (sr) 2011-04-01 2015-08-31 Novartis Ag Tretman u infekciji virusom hepatitis b zasebno ili u kombinaciji sa hepatitis delta virusom i bolesti jetre koje ih prate
KR20140011379A (ko) 2011-04-13 2014-01-28 노파르티스 아게 알리스포리비르를 사용하는 c형 간염 바이러스 감염의 치료
JP2014528947A (ja) 2011-09-27 2014-10-30 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の治療のためのアリスポリビル
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en) 2012-03-28 2013-10-03 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in specific patient subgenotype sub-population
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP3782652A1 (de) 2014-08-19 2021-02-24 Biogen MA Inc. Pegylierungsverfahren
MX377531B (es) 2015-11-03 2025-03-10 Hoffmann La Roche Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón.
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146472A (en) * 1913-10-20 1921-10-05 Standard Oil Company Of New Yo Improvements in obtaining products from petroleum by decomposition of component hydrocarbons thereof
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4275000A (en) * 1977-08-22 1981-06-23 National Research Development Corporation Peptide macromolecular complexes
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4460560A (en) * 1982-06-18 1984-07-17 University Of Southern California Drug delivery by polymeric carriers
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
EP0154316B1 (de) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
ES2065880T3 (es) 1995-03-01
DE3750906D1 (de) 1995-02-09
DE3750906T2 (de) 1995-06-29
EP0236987B1 (de) 1994-12-28
CA1336967C (en) 1995-09-12
JP2514950B2 (ja) 1996-07-10
EP0236987A2 (de) 1987-09-16
GR3015558T3 (en) 1995-06-30
EP0236987A3 (en) 1990-05-30
US5109120A (en) 1992-04-28
JPS6310800A (ja) 1988-01-18

Similar Documents

Publication Publication Date Title
DE3750906D1 (de) Chemisch modifizierte Proteine und deren Herstellung.
KR870000340A (ko) 광학 활성 피리도벤즈옥사진 유도체 및 이의 중간체의 제조방법
PT88603A (pt) Immunomodulatory azapiranes
EA200000427A1 (ru) Терапевтические применения хинолиновых производных
ATE125550T1 (de) Polypeptid und verfahren zu dessen herstellung.
KR850006404A (ko) 니트로 메틸렌 유도체의 제조방법
DE3483869D1 (de) Zusammensetzungen zur bekaempfung von toxaemia.
DK0779291T3 (da) Med heterocyclylcarbonyl substituerede benzofuranyl-urinstoffer
EA199800768A1 (ru) Новые производные эритромицина, способ их получения и их применение в качестве медикаментов
ATE36859T1 (de) 4'-demethyl-4-epipodophyllotoxin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ES543153A0 (es) Metodo de preparar derivados de b-carbolin-3-oxadiazolilo
DE3776391D1 (de) Fluessige zubereitungen von 1,2-benzisothiazolin-3-on, ihre herstellung und verwendung.
DE59509910D1 (de) Verfahren zur Herstellung von Alkylhydrogenchlorsilanen
KR850006187A (ko) 신규 히달토인(Hydantoin) 유도체의 제조방법
TR199801474T2 (xx) 2, 4-Diamino-1, 3, 5-Triazin, �retim y�ntemleri.
DK0392560T3 (da) Diaminoethylenforbindelser
BG104232A (bg) Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцин- 10-оли, метод за тяхното получаване и приложението им като лекарствени средства
ES2008962A6 (es) Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol
DE3876536D1 (de) Oxadiazol-pyrimidinone, ihre herstellung und ihre kosmetische und dermopharmazeutische verwendung.
ES2059595T3 (es) Beta-carbonil-carboxiamidas de 1,3-tiazolidinas.
KR830004210A (ko) 2-아미노-3-벤조일-페닐아세트아미드 및 환상 동족체
DK74189D0 (da) Laegemiddel til behandling af mavesaar
ATE44961T1 (de) Substituierte o-sulfonyl-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
ATE97404T1 (de) Prostazyklin-(pgi2)-analoge.
EP0289804A3 (de) Verfahren zur Herstellung von optisch aktiven Mercapto-Verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee